BIOBIJOU Co., Ltd. Logo

BIOBIJOU Co., Ltd.

Develops and manufactures injectable aesthetic solutions like HA fillers for global markets.

489460 | KO

Overview

Corporate Details

ISIN(s):
KR7489460006
LEI:
Country:
South Korea
Address:
경기도 하남시 하남대로 947 에이동 1516호, 하남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BIOBIJOU Co., Ltd. is a global medical aesthetics company established in 2018. It specializes in the research, development, manufacturing, and sale of injectable products such as skin boosters, hyaluronic acid (HA) fillers, and fat-dissolving solutions, alongside other cosmetic items. The company manages an integrated value chain, from R&D and product design to production in its own GMP-certified facilities and global distribution. BIOBIJOU has established a robust sales network, exporting to over ten countries with a strong presence in the Chinese market. Through strategic R&D alliances and investment in high-level manufacturing, the company aims to deliver high-quality, competitively priced aesthetic solutions to the global market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.4 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.8 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.9 KB
2025-05-13 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 211.9 KB
2025-05-02 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 495.1 KB
2025-05-02 00:00
Prospectus
[기재정정]투자설명서
Korean 3.6 MB
2025-04-29 00:00
Prospectus
투자설명서
Korean 3.1 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.1 MB
2025-04-07 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.0 MB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]감사보고서 (2024.12)
Korean 493.5 KB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]연결감사보고서 (2024.12)
Korean 504.6 KB
2025-03-24 00:00
Registration Form
증권신고서(지분증권)
Korean 3.0 MB
2025-03-18 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 488.6 KB
2025-03-18 00:00
Audit Report / Information
연결감사보고서 (2024.12)
Korean 499.7 KB

Automate Your Workflow. Get a real-time feed of all BIOBIJOU Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOBIJOU Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOBIJOU Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.